All About Multiple Sclerosis

More MS news articles for January 2003

Cytokine profile in patients with multiple sclerosis following vitamin D supplementation

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12507780&dopt=Abstract

J Neuroimmunol 2003 Jan;134(1-2):128-32
Mahon BD, Gordon SA, Cruz J, Cosman F, Cantorna MT.
Graduate Program in Nutrition, Pennsylvania State University, 16802, University Park, PA, USA

Multiple sclerosis (MS) patients were randomized, in a double blind design, and placed into either a vitamin D supplemented group or a placebo control group.

As expected, serum 25-hydroxyvitamin D levels increased significantly following 6 month vitamin D supplementation (17+/-6 ng/ml at baseline to 28+/-8 ng/ml at 6 months).

Vitamin D supplementation also significantly increased serum transforming growth factor (TGF)-beta1 levels from 230+/-21 pg/ml at baseline to 295+/-40 pg/ml 6 months later.

Placebo treatment had no effect on serum TGF-beta1 levels.

Tumor necrosis factor (TNF)-alpha, interferon (IFN)-gamma, and interleukin (IL)-13 were not different following vitamin D supplementation.

IL-2 mRNA levels decreased following vitamin D supplementation but the differences did not reach significance.

Vitamin D supplementation of MS patients for 6 months was associated with increased vitamin D status and serum TGF-beta1.